İNFLAMATUVAR BARSAK HASTALIKLARININ İZLEM VE TEDAVİSİ: RETROSPEKTİF BİR ÇALIŞMA

Yıl 2021, , 14 - 20, 05.01.2021

Hatice Hamarat , Tuncer Temel

https://doi.org/10.18229/kocatepetip.599555

Öz

AMAÇ: 1990–2009 yılları arasında İnflamatuvar barsak hastalığı (İBH) tanısı alan hastaların sosyo-demografik, klinik özellikleri ile teşhis ve tedavilerinin retrospektif olarak incelenmesi amaçlandı.
GEREÇ VE YÖNTEM: 1990–2009 yılları arasında Tıp Fakültesi Gastroenteroloji Kliniğinde İBH tanısı alan 237 hastanın dosya kayıtları incelenerek yapılmıştır. Hastaların yaş, cinsiyet, sigara kullanımı, endoskopi ve histopatoloji bulguları, hastalarda gelişen lokal ve sistemik komplikasyonlar, uygulanan tedavi tipleri ve cerrahi tedavi nedenleri incelenmiş ve karşılaştırılmıştır.
BULGULAR: 1990 ile 2009 yılları arasında 144 Ülseratif Kolit, 73 Crohn Hastalığı ve 20 İndetermine Kolit hastası takip edildi. Ülseratif Kolit’li hastaların teşhis anındaki tanı yaşı ortalaması 37 yıl idi. Hastaların %28,7’sinde sol kolon tutulumu, %25,2’inde pankolit ve %21 proktit tablosu mevcuttu (p<0.01). Sistemik komplikasyon olarak bir hastada eritema nodosum, üç hastada sakroileit, üç hastada primer sklerozan kolanjit, bir hastada da malign dönüşüm görüldü. Crohn hastalığı tespit edilen hastaların yaş ortalaması 35 yıl idi. Hastaların %34’ünde kolon, %64,2’sinde ince barsak tutulumu saptandı. Sistemik komplikasyon olarak dört hastada üveit, beş hastada sakroileit görüldü. 222 hasta 5-aminosalisilat (5-ASA) bilesiği tedavisi alıyordu. Immünsupresif tedavi alan 6 hasta saptandı. 159 hasta monotedavi (5-ASA), 19 hasta kombine tedavi alıyordu.
SONUÇ: Hastalığın klinik seyrinin ve klinik tablosunun belirlenmesi, uygulanacak tıbbi ve cerrahi tedavileri ve farklı subgrup hastaların takip stratejilerini saptamak için önemlidir.

Anahtar Kelimeler

Inflamatuvar Barsak Hastalıkları, Ülseratif Kolit, Crohn Hastalığı

Destekleyen Kurum

yok

FOLLOW-UP AND TREATMENT OF INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY

Öz

OBJECTIVE: The aim of this retrospective study was to investigate the socio-demographic and clinical characteristics as well as the diagnosis and treatment of patients with Inflammatory Bowel Disease between 1990 and 2009.
MATERIAL AND METHODS: Between 1990 and 2009, the records of 237 patients diagnosed with Inflammatory Bowel Disease in the Gastroenterology Clinic of Faculty of Medicine were examined. The age, sex, smoking history, endoscopy and histopathology findings of the patients, local and systemic complications developed in the patients, types of treatment applied and reasons for surgical treatment were examined.
RESULTS: Between 1990 and 2009, 144 Ulcerative Colit, 73 Crohn Disease and 20 Indeterminate Colit patients were followed. The mean age of diagnosis, at the time of diagnosis of Ulcerative Colit patients was 37 years. 28.7% patients had left colon involvement, 25.2% patients had pancolitis, and 21% patients had proctitis (p<0.01). Erythema nodosum in one patient, sacroiliitis in 3 patients, primary sclerosing cholangitis in 3 patients, and malign transformation in one patient were determined as systemic complications. The mean age was 35 years in patients with Crohn Disease. Involvement of colon and small intestine was determined in %34 and %64,2 patients, respectively. Uveitis in 4 patients, sacroiliitis in 5 patients were determined as systemic complications. 222 patients were treated with 5-ASA. Immunosuppressive treatment was given to 6 patients. 159 patients were given mono treatment (5-ASA) while 19 patients were given combine treatment.
CONCLUSIONS: Understanding of the prognosis and clinical course are important for determining medical and surgical treatment and follow up strategies for different subgroups of the patient.

Anahtar Kelimeler

Inflammatory bowel disease, Ulcerative Colitis, Crohn’s Disease

Kaynakça

• 1. Wakefield AJ, Sawyer AM, Hudson M. Smoking, the oral cotraceptive pill, and Crohn’s disease. Dig Dis Sci 1991;36(8):1147–1150. 2. Su CG, Judge TA, Lichtenstein GR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 2002;31: 307–27. 3. S.C. Truelove, L.J. Witts,Cortisone in ulcerative colitis; final report on a therapeutic trial,Br Med J, 2 (1955), pp. 1041–10484. Best WR, Becktel JM, Singleton JW et all. Development of a Crohn’s disease activity index. Gastroenterology 1979;77:829-425. Russel MG. Changes in the incidence inflammatory of bowel disease: What does it mean? Eur J Intern Med 2000; 11: 191–6.6. Rubin DT, Hanauer SB. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12(8):855-62. 7. Z.Mesut Yalın K, Bilge T, Selime A, Levent F, Semra A, Erkan P, Aysel Ü. Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases. Turk J Gastroenterol 2004; 15 (4): 238–242. 8. Gaginella, T.S. and R.E. Walsh, Sulfasalazine. Multiplicity of action. Dig Dis Sci,1992. 37(6): p. 801-12.9. Jiang L et al. Retrospective Survey of 452 Patients With Inflammatory Bowel Disease in Wuhan City, Central China. Inflamm Bowel Dis 2006;12:212–217.10. Haens GD, Baert F, Asshe V, et al. Early combined immunsupression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomized trial. Lancet. 2008;371(23):660–667.11. Sachar DB: Indications for surgery in inflammatory bowel disease: a gastroenterologist's opinion. In: Kirsner JB, ed. Inflammatory Bowel Disease. 5th ed. Philadelphia, Pa: WB Saunders Co; 611–615, 2000.